Role of Aquaporin-2 Water Channels in Urinary Concentration and Dilution Defects
| Title: | Role of Aquaporin-2 Water Channels in Urinary Concentration and Dilution Defects |
|---|---|
| Authors: | Martin, Pierre-Yves; Schrier, Robert W. |
| Publisher: | Kidney International |
| Date Published: | April 01, 1998 |
| Reference Number: | 168 |
N/A
for educational use within the NDI community. No part of this article may be reproduced in any way without permission in writing from the publisher. |
Urinary concentration defects are observed in many clinical situations. The concentrating defect can be extreme and be associated with serious clinical consequences, such as in central diabetes insipidus. Alternatively, the concentration defect may be mild as occurs in the nephrotic syndrome. Whatever its severity, this concentrating defect reflects a perturbation in renal solute-free water handling. Arginine vasopressin (AVP), or antidiuretic hormone, plays a central role in the regulation of water balance. Recently, the action of AVP on the permeability of the apical membrane of the principal cells in the collecting duct has been demonstrated to be mediated by a water channel protein, named originally aquaporin-CD (that is, collecting duct), and now aquaporin-2 (AQP-2). The cloning of this water channel and the studies demonstrating its functional capacity in response to vasopressin have been hallmarks in the understanding of the water regulation by the kidneys. This review will first briefly describe the family of aquaporins. The major mechanisms of regulation of water balance by the AVP-mediated AQP-2 pathway and the different clinical situations wherein alterations in AQP-2 occur will then be discussed.
THE AQUAPORINS
The aquaporin family is a group of selective water channels, which is a part of the larger family of MIP intrinsic membrane proteins. To date, eight different aquaporins have been cloned and aquaporins-1 through -4 have been identified within the kidney and play a role in the water reabsorption of the glomerular filtrate along the nephron. Aquaporin-1 (AQP-1) has been localized to both the apical and basolateral membranes of the proximal tubules and descending limb of Henle, nephron segments that are constitutively water-permeable [1]. It is postulated to be the most important water channel in these segments, but not the only one, since individuals who lack functional AQP1 do not have clinical disturbances of water conservation [2]. This interesting observation raised the possibility of other membrane proteins able to transport water. The recent evidence of water transport by the glucose cotransporters, which are abundant in the proximal tubule may be an alternative way for the tubules to transport water [3]. AQP3 and AQP4 are localized to the basolateral membrane of principal cells of the collecting ducts, AQP3 being located predominantly in the cortical and outer medulla, whereas AQP4 predominates in the inner medullary collecting duct (IMCD) [4, 5]. These water channels are constantly expressed on the membranes, thus providing a pathway for water movement from the principal cells to the hypertonic medullary interstitium. The expression of AQP3, but not AQP4, has also been shown to be modulated by AVP [6]. The clinical importance of these two water channels in the renal water conservation has yet to be determined. There is [sic] no known natural mutations of AQP3 and AQP4. Recently, a transgenic mice [sic] deficient in AQP4 has been generated [7]. Interestingly, the phenotype abnormalities were very subtle, with a small defect in maximal urinary concentration, consistent with the predominant localization of AQP4 in the lower portion of the IMCD.
ARGININE VASOPRESSIN-AQUAPORIN-2 PATHWAY
Arginine vasopressin release
Arginine vasopressin is released into the systemic circulation from the neurohypophysis, an extension of the ventral hypothalamus located in the dorsal and caudal surfaces of the adenohypophysis. The neurohypophysis is mainly composed of a capillary network and neurosecretory axons that originate in the magnocellular neurons of the supraoptic and paraventricular nuclei of the hypothalamus. AVP is synthesized as a preprohormone composed of a signal peptide AVP, neurophysin and a glycoprotein. The preprohormone is synthesized in neuronal bodies of the supraoptic and paraventricular neuclei, packaged in secretory granules, and transported down the axons. During this process, AVP and neurophysin are removed from the preprohormone by proteolytic cleavage and stored in the nerve terminals in the neurohypophysis until secreted by a calcium-dependent exocytic process.
Renal action of arginine vasopressin
The cellular actions of AVP are mediated by at least three types of G-protein-coupled receptors: the V1a (vascular and hepatic), the V1b (anterior pituitary) and the V2, which is the collecting duct receptor responsible for the renal action of AVP on water excretion. The V2 receptors are located on the basolateral membrane of the collecting duct cells. AQP2 is a selective, mercurial-sensitive, water channel cloned and characterized in rats [8] and in humans [9]. This water channel is expressed almost exclusively within the kidney principal cells of the collecting duct. A quantitative analysis using a single tubule ELISA method demonstrated that AQP2 was extremely abundant throughout the collecting duct, thus accounting for the rapid osmotic water transport measured in these nephron segments [10]. The connecting tubules from the renal arcade segment have also been demonstrated to contain AQP2 in the rat [11]. When inserted in the apical membrane, AQP2 allows the selective passage of water, which then crosses the basolateral membrane through the constitutively present AQP3 and AQP4 water channels. The hypertonic interstitium provides the osmotic driving forces. AQP2, like the other aquaporins, is a six membrane-spanning region with both the amino-terminal and the carboxy terminal tails located intracellularly. The three-dimensional conformation of AQP2 is not known but different models have been provided. The most attractive being the hourglass model proposed for AQP1 in which two hydrophilic loops containing Asn-Prol-Ala sequences are folded into the lipid bilayer, forming a single aqueous pore [12].
Short term action. The binding of AVP activates 3',5' cyclic adenosine monophosphate (cAMP) formation, via the stimulatory Gsa protein, which then activates a process whereby the cytosolic AQP2 moves to the apical membrane, thereby increasing the water permeability. There is now a strong body of evidence that the plasma membrane expression of AQP2 in principal cells is mediated by AVP [13-15]. The increased apical membrane content of AQP2 occurs via the exocytotic insertion of transport vesicles enriched in AQP2 protein that contains the necessary information to target the membrane [16]. It has been also shown in LLC-PK1 cells that this vasopressin-induced trafficking of AQP2 was dependent upon PKA-induced phosphorylation rather than the water permeability of AQP2 molecule [17]. This may provide an explanation for the controversial results concerning the role of phosphorylation in the action of AVP [18, 19]. Decreased plasma AVP concentration down-regulates the AQP2 membrane expression by promoting an endocytic retrieval of the transport vesicle enriched in AQP2, thus decreasing the water permeability of the apical membrane. This translocation from the apical membrane to the cytoplasmic vesicles and vice versa is microtubule-dependent [20]. This trafficking-regulated pathway is the basis of the ?shuttle hypothesis,? it is dependent on the short term action of AVP, is fast and is rapidly reversible [21]. This shuttle hypothesis has been supported by the recycling of the AQP2 proteins which has been very nicely demonstrated in vitro in LLC-PK1 cells transfected with AQP2 [22].
Long term action. In addition to this short term action, the abundance of AQP2 can also be regulated, thus influencing the basal water permeability as well as the magnitude of the permeability effect following exocytosis or endocytosis of AQP2 [14, 23]. For instance, during chronic fluid deprivation the collecting duct can attain a higher water permeability because of the larger number of AQP2 available to be translocated to the apical membrane. An increased amount of AQP2 mRNA and protein occurs in this setting [24]. In the collecting ducts of the rat model of central insipidus diabetes (Brattelboro rats), the lack of AVP is associated with a very low basal water permeability, a low content of AQP2 and a moderate response to acute administration of AVP. Chronic administration of AVP (7 days), however, increases the basal and maximal permeability of the Brattelboro collecting ducts, and this is associated with an increase in AQP2 protein content [23]. This long term effect is therefore mediated by AVP and implies new synthesis of AQP2 protein and mRNA [24]. The molecular basis of this long-term regulation by AVP is explained by the presence in the promoter region of the human AQP2 gene of a cAMP response element (CRE), which promotes the transcription of AQP2 mRNA [9]. Moreover, it has been recently shown that cAMP activation by the V2 receptor has a dual effect on CRE and the immediate early gene expression, c-Fos/c-Jun, which activates the AP1 promoter site [25]. AVP-independent regulation of AQP2 expression has also to be considered, and oxytocin has been demonstrated to up-regulate the expression of AQP2 via the V2 receptor [26]. In addition, inner medullary tonicity may also contribute to this long term regulation of AQP2 as suggested by the results of in vivo studies [27].
Urinary aquaporin-2
AQP2 protein can be measured in the urine either by radioimmunoassay [28] or by Western blot [29] and appears to be a good index of the action of AVP on the collecting duct. With respect to the "shuttle hypothesis" and the recycling of AQP2 protein, this finding means that a percentage of the AQP2 protein anchored in the membrane is not recycled, but lost in the lumen and then washed out by the urine. Thus, the more AQP2 present within the membrane, the more AQP2 that is lost in the urine. Thus, urinary AQP2 provides a potential biologic marker of AVP action in humans. The studies measuring urinary AQP2 will be discussed below depending on the pathophysiological situation.
CONCENTRATING DEFECTS
Hereditary
Central diabetes insipidus. In the Brattleboro rats as well as in humans with familial autosomal-dominant central diabetes insipidus, the inability to release AVP is due to a mutated peptide that cannot be processed at the level of the endoplasmic reticulum into the neurosecretory vesicles. The majority of the mutations, but not all, have been shown to reside primarily in the neurophysin coding region [30]. The importance of neurophysin in the processing and secretion of AVP has been recently demonstrated in COS cells tranfected [sic] with different constructs of the AVP gene precursor [31].
Absence of circulating AVP is associated in Brattelboro rats with a very low content of AQP2 protein in the collecting duct cytosol, and AVP administration significantly increases this AQP2 content [23]. The radioimmunoassay of urinary excretion of AQP2 was very low during water restriction in five patients with central diabetes insipidus and was increased five times by the injection of the V2 analog desmopressin (DDAVP) [28]. Moreover, the urinary AQP2 response to a hypertonic saline infusion test and to AVP infusion has been shown to be a useful tool for the diagnosis of central diabetes insipidus [32].
Nephrogenic diabetes insipidus. In most families, nephrogenic diabetes insipidus is caused by a mutation in the gene for the vasopressin V2 receptor on the chromosome X (X-linked recessive), but approximately 10% of the families show an autosomal recessive pattern of inheritance. Among this autosomal recessive nephrogenic diabetes insipidus, an AQP2 mutation with intact V2 receptor was shown recently to account for the insensitivity of the collecting duct to the action of AVP [33]. This observation in humans established the link between AQP2 and AVP in the regulation of water renal excretion. Since then, additional cases of AQP2 mutations have been reported. It has been demonstrated in vitro that at least one cause underlying the defect in water permeability is a misrouting of the AQP2 mutant protein, rather than a dysfunction of the water channel [34]. By expressing six missense AQP2 proteins in Xenopus oocytes, the authors demonstrated nicely that the transport to the plasma membrane was impaired, the AQP2 mutant proteins apparently being retained in the endoplasmic reticulum.
Therefore, based on these observations, it appears that two out of three forms of inherited diabetes insipidus are caused by a gene mutation altering the protein trafficking.
Acquired nephrogenic diabetes insipidus
|
Hypokalemia. Potassium depletion is commonly associated with a mild to moderate impairment of urinary concentrating ability (Table 1). It was known that the accompanying polyuria was AVP-resistant, but the mechanism was unclear. It was postulated that the cAMP sensitivity to AVP was decreased, while in the toad bladder it was [sic] been demonstrated that a defect distal to cAMP might occur [35]. Down-regulation of AQP2 in potassium-depleted rats provided a further insight into the cause of the collecting duct resistance to AVP [36]. The decreased expression of AQP2 in the hypokalemic rats correlated with the lower urinary osmolality and was similar in both the cortex and the medulla, thus suggesting that the AQP2 down-regulation was, at least partially, independent of the medullary tonicity. The cortical effect was important to demonstrate because of the known inhibitory effect of hypokalemia on the NaCl reabsorption of the thick ascending limb (TAL), which would decrease medullary, but not cortical, tonicity. In addition, furosemide was administered in another group of control rats to decrease the medullary gradient [35]. Furosemide, although decreasing urine osmolality did not down-regulate AQP2 expression, thus further suggesting that medullary tonicity is not involved in the down-regulation of AQP2. Repletion of potassium corrected the AQP2 down-regulation and re-established a normal urinary concentration (Fig. 1).
Lithium. Polyuria is a frequent side effect in bipolar depressive patients treated with lithium.
|
Hypercalcemia. Hypercalcemia and hypercalciuria produce a renal concentrating defect, which is resistant to AVP. The mechanism of this cellular resistance to AVP is not known but may be due to luminal rather than extracellular calcium concentration. Recently, a microperfusion study demonstrated a role for the apical extracellular calcium sensing receptor (CaSR), which has already been incriminated in the NaCl and calcium reabsorption of the thick ascending limb (TAL) [39] and in the regulation of water permeability of the IMCD [40]. This CaSR specifically reduces AVP-elicited osmotic water permeability when luminal calcium increases. Teleologically, this may be to prevent a potential risk of precipitation of calcium oxalate or phosphate. The CaSR protein is located on the apical membrane of the principal cells within the same endosomes, which contain AQP2 proteins, as well as stimulatory and inhibitory GTP binding proteins, and two isoforms of protein kinase C (PKC) [40]. The authors postulate the existence of a unique apical IMCD membrane signaling mechanism linking calcium and water metabolism, thus providing a first line control of alterations in luminal calcium concentrations. Thus, hypercalciuria may downregulate AQP2 expression or interfere with the AQP2 trafficking. The in vivo demonstration of a down-regulation of AQP2 during hypercalcemia and/or hypercalciuria, which could account for the nephrogenic diabetes insipidus during hypercalcemia, has not yet been reported. Finally, as already stated in the hypokalemia-induced down-regulation, the effect of hypercalcemia along the nephron, such as the decreased NaCl reabsorption in TAL through its basolateral CaSR, may also participate in the urinary concentrating defect by decreasing the medullary osmotic driving force for passive water movement.
Low protein diet. Decreased protein intake diminishes urine concentrating capacity and has been shown to be partially due to an increase in urea reabsorption in the initial IMCD, thus resulting in a decrease urea delivery in the deeper IMCD. The resultant decrease in hypertonicity of the deep medullary interstitium may therefore decrease the osmotic driving force to reabsorb water. In addition, it has been shown that the terminal IMCD of low-protein fed rats have a localized down-regulation of AQP2, which is not present in the other part of the nephron [27]. This mechanism could therefore contribute to the urinary concentrating defect associated with a low protein diet. The persistent integrity of the cortical collecting duct and the initial IMCD may explain why the defect is mild.
Nephrotic syndrome. Defects in both diluting and concentrating capacity have been documented in nephrotic syndrome. Whereas the diluting ability defect has been explained by a non-osmotic release of AVP [41], the concentrating defect has not been elucidated. Using the puromycin aminonucleoside (PAN)-induced nephrotic syndrome model in rats, Apostol et al [sic] found an extensive down-regulation of AQP2 and AQP3 water channels in IMCD [42]. Interestingly, this down-regulation was observed in the presence [of] normal plasma sodium and elevated plasma AVP concentrations, thus suggesting an unresponsiveness of the IMCD cells to the action of AVP. In addition, the countercurrent multiplier mechanism was assessed by the simultaneaous [sic] measurement of inner medullary tissue osmolality. Although decreased in PAN-treated rats, the inner medullary tissue osmolality was not as profoundly decreased as the maximal urinary osmolality, thus implicating a failure of complete osmotic equilibration across the IMCD, compatible with the AQP2 down-regulation [42].
Bilateral and unilateral ureteral obstruction. Polyuria is common after reversal of urinary tract obstruction and the associated defect in urine concentrating capacity can last for several days. A down-regulation of AQP2 has been demontrated [sic] in rat models of both bilateral and unilateral ureteral obstructions. The unilateral ureteral obstruction [43] was studied to exclude a role in the solute diuresis inherent to the relief of bilateral ureteral obstruction [44]. These unilateral experiments demonstrated that intrarenal factors, such as intrarenal pressure or prostaglandin production, may play a role in this AQP2 down-regulation. Interestingly, a mild down-regulation of AQP2 was also present in the contralateral unobstructed kidney, thus suggesting that a circulating factor may also contribute to the adaptative mechanism.
Vasopressin escape. In situations where AVP is inappropriately high relative to plasma osmolality such as the syndrome of inappropriate antidiuretic hormone secretion (SIADH), chronic heart failure (CHF) and cirrhosis, the degree of hypoosmolality is limited, and a counterregulatory mechanism has been proposed and termed vasopressin escape. One explanation for this mechanism has been proposed through a down-regulation of the AVP-elicited enhanced AQP2 expression [45]. Rats were infused with constant doses of AVP, thus mimicking a situation of non-osmotic release of AVP, and then subjected to a liquid diet. The onset of vasopressin escape, indicated by an increase in urine flow, was observed by day 2 of water loading and coincided with a decrease in the AVP-induced AQP2 expression. This escape phenomenon was not associated with a change in the high membrane/cytosol ratio of AQP2 elicited by AVP, suggesting that the escape phenomenon may be a counterregulatory mechanism of the action of AVP on AQP2 synthesis, but not on AQP2 trafficking. It should be emphasized, however, that the plasma sodium necessary to stimulate this escape mechanism was lower than the majority of hypoosmolality encountered in clinical situations, such as cirrhosis and chronic heart failure (that is, < 110 mmol/liter).
Increased AQP2 expression
Syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Chronic administration of AVP in rats ingesting a liquid diet, a model of SIADH, elicits an increase expression of AQP2 which mediates the increased solute-free water reabsorption responsible for the hypoosmolality. The increase in AQP2 mRNA appears very rapidly (less than 6 hr after the starting dose) and is followed by an increase in AQP2 protein content. This increase is reversed by the blockade of AVP action [46].
Chronic heart failure (CHF). CHF is a situation involving renal water and sodium retention. Pretreatment hyponatremia is common in severe CHF and has been shown to be an ominous prognostic factor. Non-osmotic release of AVP is the cause of the hypoosmolality and administration of a V2 receptor antagonists [sic] corrects the hypoosmolality in rats. Moreover, administration of a V2 receptor antagonist improved the long-term mortality of chronic heart failure rats [47].
|
Cirrhosis. Renal salt and water retention is also a hallmark of advanced cirrhosis with ascites. Non-osmotic release of AVP has been demonstrated in cirrhosis and accounts for the high incidence of hyponatremia observed in hospitalized cirrhotic patients with ascites. This non-osmotic release of AVP is also observed in the CCl4-induced cirrhosis rat model and is related to the hyperdynamic circulation elicited by the peripheral arterial vasodilation [52]. AQP2 has been demonstrated to be increased in cirrhotic rats with ascites [46, 53] and this increase was reversed by the administration of a V2 receptor antagonist [46]. No immunocytochemical localization was however performed in these two studies to investigate an effect on AQP2 trafficking.
Physiological alterations of AQP2
Newborn. Newborn humans and most mammals cannot concentrate their urine and there is no correlation between urine osmolality and plasma AVP concentrations, which are usually high in the postnatal period. Using the rat model it has been demonstrated that newborn rats have a very low expression of AQP2 and that AQP2 increases from infancy to adulthood, thus paralleling the increase in urine concentrating capacity [54]. Administration of glucocorticoid hormones significantly increased AQP2 mRNA and protein expression as well as urinary concentrating capacity in infant rats, whereas it had no effect on AQP2 expression in adult rats. It should be emphasized that the increase in mRNA was detectable only after 24 hours of hormone administration, in contrast to the rapid effect of AVP on the AQP2 mRNA of adult rats [55]; thus, there may be an intermediary step for the action of the glucocorticoids on AQP2 mRNA. In any case, these findings demonstrate that AQP2 plays a major role in the concentrating defect of infancy and that glucocorticoids promote their expression.
Pregnancy. Pregnancy is characterized by an increase in body fluid volume. Expression of AQP2 protein and mRNA has been shown to be elevated as early as the end of the first trimester of pregnancy in rats and appears to contribute to the water retention of pregnancy [56]. Indeed, although plasma AVP concentration in pregnant rats was not significantly different from non-pregnant rats, there was a significant increase in AQP2 which coincided with the occurrence of hypoosmolality. The same study demonstrated that this increase in AQP2 was reversed by V2 receptor antagonism, thus implicating a V2-mediated effect on AQP2 synthesis. Since oxytocin can also activate the V2 receptor, a role of this hormone cannot be excluded.
CONCLUSION
The recent discovery of AQP2 water channel has provided a new tool to unveil the physiological and pathophysiological mechanisms of water homeostasis as regulated by AVP. The dual short and long term regulation by AVP of AQP2 via an adenylate cyclase-coupled receptor demonstrates the physiological adaptative mechanisms to excrete or conserve water. In addition to inherited nephrogenic diabetes insipidus due to AQP2 mutations, several acquired nephrogenic diabetes insipidus are due, at least partially, to AQP2 dysfunction. The mechanisms have yet to be elucidated, but it appears that this dysfunction implies altered synthesis and/or trafficking of AQP2 protein. Finally, the availability to measure urinary AQP2 presents a new biological marker of AVP action on collecting duct in humans and could be also helpful to monitor the action of V2 AVP receptor antagonists.
REFERENCES
- Nielsen S, Smith BL, Christensen EI, Knepper MA, Agre P: CHIP28 water channels are localized in constitutively water-permeable segments of the nephron. J Cell Biol 120:371-383, 1993
- Preston GM, Smith BL, Zeidel ML, Moulds JJ, Agre P: Mutations in aquaporin-1 in phenotypically normal humans without functional CHIP water channels. Science 265:1585-1587, 1994
- Loo DD, Zeuthen T, Chandy G, Wright EM: Cotransport of water by the Na+/glucose cotransporter. Proc Natl Acad Sci USA 93:13367-13370, 1996
- Ecelbarger CA, Terris J, Frindt G, Echevarria M, Marples D, Nielsen S., Knepper MA: Aquaporin-3 water channel localization and regulation in rat kidney. Am J Physiol 269(5 Pt 2):F663-F672, 1995
- Terris J, Ecelbarger CA, Marples D, Knepper, MA, Nielsen S: Distribution of aquaporin-4 water channel expression within rat kidney. Am J Physiol 269(6 Pt 2):F775-F785, 1995
- Terris J, Ecelbarger CA, Nielsen S, Knepper, MA: Long-term regulation of four renal aquaporins in rats. Am J Physiol 271:F414-F422, 1996
- Ma T, Yang B, Gillepsie AM, Carlson EJ, Epstein CJ, Verkman AS: Generation and phenotype of a transgenic knockout mouse lacking the mercurial-insensitive water channel aquaporin-4. J Clin Invest 100:957-962, 1997
- Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S: Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature Lond 361:549-552, 1993
- Uchida S, Sasaki S, Fushimi K, Marumo F: Isolation of human aquaporin-CD gene. J Biol Chem 269:23451-23455, 1994
- Kishore BK, Terris JM, Knepper MA: Quantitation of aquaporin-2 abundance in microdissected collecting ducts: Axial distribution and control by AVP. Am J Physiol 271(1 Pt 2):F62-F70, 1996
- Kishore BK, Mandon B, Oza NB, DiGiovanni SR, Coleman RA, Ostrowski NL, Wade JB, Knepper MA: Rat renal arcade segment expresses vasopressin-regulated water channel and vasopressin V2 receptor. J Clin Invest 97:2763-2771, 1996
- Preston GM, Jung JS, Guggino WB, Agre P: Membrane topology of aquaporin CHIP. Analysis of functional epitope-scanning mutants by vectorial proteolysis. J Biol Chem 269:1668-1673, 1994
- Yamamoto T, Sasaki S, Fushimi K, Kawasaki K, Yaoita E, Oota K, Hirata Y, Marumo F, Kihara I: Localization and expression of a collecting duct water channel, aquaporin, in hydrated and dehydrated rats. Exp Nephrol 3:193-201, 1995
- Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA: Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 92:1013-1017, 1995
- Marples D, Knepper MA, Christensen EI, Nielsen S: Redistribution of aquaporin-2 water channels induced by vasopressin in rat kidney inner medullary collecting duct. Am J Physiol 269(3 Pt 1):C655-C664, 1995
- Katsura T, Verbavatz JM, Farinas J, Ma T, Ausiello DA, Verkman AS, Brown D: Constitutive and regulated membrane expression of aquaporin-1 and aquaporin-2 water channels in stably transfected LLC-PK1 epithelial cells. Proc Natl Acad Sci USA 92:7212-7216, 1995
- Katsura T, Gustafson CE, Ausiello DA, Brown D: Protein kinase A phosphorylation is involved in regulated exocytosis of aquaporin-2 in transfected LLC-PK1 cells. Am J Physiol 272:F816-F822, 1997
- Lande MB, Jo I, Zeidel ML, Somers M, Harris HWJ: Phosphorylation of aquaporin-2 does not alter the membrane water permeability of rat papillary water channel-containing vesicles. J Biol Chem 271:5552-5557, 1996
- Kuwahara M, Fushimi K, Terada Y, Bai L, Marumo F, Sasaki S: cAMP-dependent phosphorylation stimulates water permeability of aquaporin-collecting duct water channel protein expressed in Xenopus oocytes. J Biol Chem 270:10384-10387, 1995
- Sabolic I, Katsura T, Verbavatz JM, Brown D: The AQP2 water channel: Effect of vasopressin treatment, microtubule disruption, and distribution in neonatal rats. J Membr Biol 143:165-175, 1995
- Wade JB, Stetson DL, Lewis SA: ADH action: Evidence for a membrane shuttle mechanism. Ann N Y Acad Sci 372:106-117, 1981
- Katsura T, Ausiello DA, Brown D: Direct demonstration of aquaporin-2 water channel recycling in stably transfected LLC-PK1 epithelial cells. Am J Physiol 270:F548-F553, 1996
- DiGiovanni SR, Nielsen S, Christensen EI, Knepper MA: Regulation of collecting duct water channel expression by vasopressin in Brattleboro rat. Proc Natl Acad Sci USA 91:8984-8988, 1994
- Yamamoto T, Sasaki S, Fushimi K, Ishibashi K, Yaoita E, Kawasaki K, Marumo F, Kihara I: Vasopressin increases AQP-CD water channel in apical membrane of collecting duct cells in Brattleboro rats. Am J Physiol 268(6 Pt 1):C1546-C1551, 1995
- Yasui M, Zelenin SM, Celsi G, Aperia A: Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements. Am J Physiol 272:F443-F450, 1997
- Chou CL, DiGiovanni SR, Luther A, Lolait SJ, Knepper MA: Oxytocin as an antidiuretic hormone. II. Role of V2 vasopressin receptor. Am J Physiol 269(1 Pt 2):F78-F85, 1995
- Sands JM, Naruse M, Jacobs JD, Wilcox JN, Klein JD: Changes in aquaporin-2 protein contribute to the urine concentrating defect in rats fed a low-protein diet. J Clin Invest 97:2807-2814, 1996
- Kanno K, Sasaki S, Hirata Y, Ishikawa S, Fushimi K, Nakanishi S, Bichet DG, Marumo F: Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med 332:1540-1545, 1995
- Elliot S, Goldsmith P, Knepper M, Haughey M, Olson B: Urinary excretion of aquaporin-2 in humans: A potential marker of collecting duct responsiveness to vasopressin. J Am Soc Nephrol 7:403-409, 1996
- Rittig S, Robertson GL, Siggard C, Kovacs L, Gregersen N, Nyborg J, Pedersen EB: Identification of 13 new mutations in the vasopressin-neurophysin II gene in 17 kindreds with familial autosomal dominantneurohypophyseal diabetes insipidus. Am J Hum Genet 58:107-117, 1996
- Kim JK, Summer SN, Wood WM, Brown JL, Schrier RW: Arginine vasopressin (AVP) secretion with mutants of wild-type and Brattleboro rats AVP gene. J Am Soc Nephrol 8:1863-1869, 1997
- Saito T, Ishikawa S, Sasaki S, Nakamura T, Rokkaku K, Kawakami A, Honda K, Marumo F, Saito T: Urinary excretion of aquaporin-2 in the diagnosis of central diabetes insipidus. J Clin Endocrinol Metab 82:1823-1827, 1997
- Deen PM, Verdijk MA, Knoers NV, Wieringa B, Monnens LA, van Os CH, van Oost BA: Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 264:92-95, 1994
- Mulders SM, Knoers NVAM, Van Lieburg AF, Monnens LAH, Leumann E, Wuhl E, Schober E, Rijss JPL, van Os CH, Deen PMT: New mutations in the AQP2 gene in nephrogenic diabetes insipidus resulting in functional but misrouted water channels. J Am Soc Nephrol 8:242-248, 1997
- Finn AL, Handler JS, Orloff J: Relation between bladder potassium content and permeability response to vasopressin. Am J Physiol 210:1279-1284, 1966
- Marples D, Frokiaer J, Dorup J, Kneper MA, Nielsen S: Hypokalemia-induced downregulation of aquaporin 2 water channel expression in rat kidney medulla and cortex. J Clin Invest 97:1960-1968, 1996
- Forrest JN, Cohen AD, Toretti J, Himmelhoch JM, Epstein FH: On the mechanism of lithium-induced diabetes insipidus in man and the rat. J Clin Invest 53:1115-1123, 1974
- Marples D, Christensen S, Christensen EI, Ottosen PD, Nielsen S: Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest 95:1838-1845, 1995
- Hebert SC, Brown EM, Harris HW: Role of the Ca-sensing receptor in divalent mineral ion homeostasis. J Exp Biol 200:295-302, 1997
- Sands JM, Naruse M, Baum M, Jo I, Hebert SC, Brown EM, Harris HW: Apical extracellular calcium/polyvalent cation sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. J Clin Invest 99:1399-1405, 1997
- Gines P, Abraham WT, Schrier RW: Vasopressin in pathophysiological states. Semin Nephrol 14:384-397, 1994
- Apostol E, Ecelbarger CA, Terris J, Bradford AD, Andrews P, Knepper MA: Reduced renal medullary water channel expression in puromycin aminonucleoside-induced nephrotic syndrome. J Am Soc Nephrol 8:15-24, 1997
- Frokiaer J, Christensen BM, Marples D, Djurhuus JC, Jensen UB, Knepper MA, Nielsen S: Downregulation of aquaporin-2 parallels changes in renal water excretion in unilateral ureteral obstruction. Am J Physiol 273:F213-F223, 1997
- Frokiaer J, Marples D, Knepper MA, Nielsen S: Bilateral ureteral obstruction downregulates expression of vasopressin-sensitive AQP-2 water channel in rat kidney. Am J Physiol 270(4 Pt 2):F657-F668, 1996
- Ecelbarger CA, Nielsen S, Olson BR, Murase T, Baker EA, Knepper MA: Role of renal aquaporins in escape from vasopressin-induced antidiuresis in rat. J Clin Invest 99:1852-1863, 1997
- Fujita N, Ishikawa SE, Sasaki S, Fujisawa G, Fushimi K, Marumo F, Saito T: Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats. Am J Physiol 269(6 Pt 2):F926-F931, 1995
- Nishikimi T, Kawano Y, Saito Y, Matsuoka H: Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 27:275-282, 1996
- Abraham WT, Oren RT, Robertson AD, Schrier RW: Effect of an oral, nonpeptide selective V2 receptor AVP antagonist in human heart failure. Proceedings of the 14th International Congress of Nephrology 1:S15, 1997
- Nielsen S, Terris J, Andersen D, Ecelbarger C, Frokiaer J, Jonassen T, Marples D, Knepper MA, Petersen JS: Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc Natl Acad Sci USA 94:5450-5455, 1997
- Xu D-L, Martin P-Y, Ohara M, St John J, Pattison T, Meng X, Morris K, Kim JK, Schrier RW: Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 99:1500-1505, 1997
- Martin PY, Abraham WT, Xu L, Oren RM, Olson BR, Ohara M, Schrier RW: Selective V2 receptor AVP antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. (abstract) J Am Soc Nephrol 8:A0103, 1997
- Niederberger M, Martin PY, Gines P, Morris K, Tsai P, Xu DL, McMurtry I, Schrier RW: Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 109:1624-1630, 1995
- Asahina Y, Izumi N, Enomoto N, Sasaki S, Fushimi K, Marumo F, Sato C: Increased gene expression of water channel in cirrhotic rat kidneys. Hepatology 21:169-173, 1995
- Yasui M, Marples D, Belusa R, Eklof AC, Celsi G, Nielsen S, Aperia A: Development of urinary concentrating capacity: Role of aquaporin-2. Am J Physiol 271(2 Pt 2):F461-F468, 1996
- Saito T, Ishikawa S, Sasaki S, Fujita N, Fushimi K, Okada K, Takeuchi K, Sakamoto A, Ookawara S, Kaneko T, Marumo F, Saito T: Alteration in water channel AQP-2 by removal of AVP stimulation in collecting duct cells of dehydrated rats. Am J Physiol 272:F183-F191, 1997
- Ohara M, Martin PY, Xu DL, Ohara M, Martin PY, Xu DL, St John J, Pattison T, Kim JK, Schrier RW: Upregulation of aquaporin 2 water channel expression in pregnant rats. J Clin Invest (in press)
Robert W. Schrier, M.D. Department of Medicine University of Colorado Health Sciences Center 4200 East 9th Avenue Denver, Colorado 80262, USA E-mail: robert.schrier@uchsc.edu |
This translation by the NDI Foundation is to assist the lay reader. To provide a clear, accessible interpretation of the original article, we eliminated or simplified some technical detail and complicated scientific language. We concentrated our translation on those aspects of the article dealing directly with NDI. The NDI Foundation thanks the researchers for their work toward understanding and more effectively treating this disorder.
© Copyright NDI Foundation 2007 (JC)
When water is filtered through the kidney, it passes through the nephrons, the main functional units of the kidney. There are about a million of them in each kidney. Each nephron consists of a filtering unit called a glomerulus which is attached to a little tube called a tubule. The tubule has several sections in it and each section has a different effect on the body water passing through it. Some sections reabsorb the water into the inner tissues of the kidney and some do not. The body water passes out of the tubule and into the collecting duct, which usually allows much of the body water to be reabsorbed into the kidney inner tissue. It can do this because, when signaled by AVP, AQP2s insert themselves into the membranes of the principal cells of the collecting duct, making them more water permeable than normal so more water can flow through them and be reabsorbed by the body. The remaining fluid becomes concentrated urine that is excreted. Normally, most of the AQP2s shuttle back from the membrane into the inside of the cell after they have performed their function; however, some are washed out with the urine. The more AQP2s within the membrane, the more will be washed out. Thus, the amount of AQP2s in the urine can serve as an indicator of AVP action in humans.
In nephrogenic diabetes insipidus (NDI), the patient's kidneys do not respond to the message of AVP, do not reabsorb the water passing through them, and therefore, do not concentrate urine. In the inherited forms of NDI, this is most often due to a mutation in the vasopressin-2 receptor (V2R) gene. But in about 10% of the cases it is due to mutations in the AQP2 gene which results in defective AQP2s. To date, researchers have established that most of the different AQP2 gene mutations result in AQP2s that can't travel to the cell membrane in response to AVP. Since they stay inside the cell and don't travel to the cell membrane, they can't make the cell membrane more water permeable. Thus, the collecting duct isn't able to reabsorb the water and it is excreted from the body as dilute urine.
NDI can also be acquired through a variety of means, some of which affect AQP2s. For example, a low level of blood potassium can induce NDI. One experiment on animals demonstrated how low potassium blood levels reduced the amount of AQP2s in cells resulting in a reduced ability to concentrate urine. When the animals' diet was changed in order to bring the potassium levels to normal, their number of AQP2s expressed returned to normal, as did their ability to concentrate urine.
Long-term use of the drug lithium, often prescribed for certain psychological disorders, can induce NDI. Some research suggests that lithium also reduces the amount of AQP2 that is expressed in the cells. Too much blood calcium may also trigger the down-regulation of AQP2 expression, as may a low protein diet and bilateral and unilateral obstructions of the ureter.
That AQP2 plays a vital role in the kidneys' ability to concentrate urine by allowing the collecting duct to reabsorb body water is further shown by looking at newborns. Newborns can't concentrate urine. They also have a very low level of AQP2 expression. As they grow, their ability to concentrate urine is paralleled by increased expression of AQP2.